The Joint Task Force for Eradication of Stock Price Manipulation has launched a compulsory investigation into a KOSDAQ-listed bio company referred to as Company A and its employees, who are suspected of making illicit profits using undisclosed information before public disclosure.


"Bought Shares Knowing Good News in Advance"... Joint Task Force Raids Kosdaq Bio Company View original image

According to the financial sector on September 15, the task force is currently conducting a search and seizure at the headquarters of Company A in Gangnam-gu, Seoul as well as the residences of its employees.


More than 10 individuals, including employees of Company A, are suspected of acquiring shares before the announcement of a technology transfer agreement between Company A and a global pharmaceutical company regarding new drug development, and then selling the shares for a profit after the stock price surged following the disclosure. These actions reportedly resulted in approximately 1 billion won in illicit gains.


Company A disclosed last year that it had signed technology transfer agreements related to new drug development with a global pharmaceutical company both in the first and second half of the year. The company's stock price soared after the disclosures.



"Bought Shares Knowing Good News in Advance"... Joint Task Force Raids Kosdaq Bio Company View original image


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing